NASDAQ:PRTK - Paratek Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$10.30 -0.10 (-0.96 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$10.30
Today's Range$10.15 - $10.40
52-Week Range$10.10 - $29.00
Volume583,130 shs
Average Volume622,790 shs
Market Capitalization$328.60 million
P/E RatioN/A
Dividend YieldN/A
Beta0.49

About Paratek Pharmaceuticals (NASDAQ:PRTK)

Paratek Pharmaceuticals logoParatek Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.

Receive PRTK News and Ratings via Email

Sign-up to receive the latest news and ratings for PRTK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:PRTK
CUSIP89354M10
Phone617-807-6600

Debt

Debt-to-Equity Ratio0.47
Current Ratio8.06
Quick Ratio8.06

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$12.62 million
Price / Sales25.79
Cash FlowN/A
Price / CashN/A
Book Value$3.51 per share
Price / Book2.93

Profitability

EPS (Most Recent Fiscal Year)($3.30)
Net Income$-89,060,000.00
Net Margins-707.08%
Return on Equity-87.29%
Return on Assets-50.20%

Miscellaneous

Employees83
Outstanding Shares31,600,000

Paratek Pharmaceuticals (NASDAQ:PRTK) Frequently Asked Questions

What is Paratek Pharmaceuticals' stock symbol?

Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK."

How were Paratek Pharmaceuticals' earnings last quarter?

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) issued its earnings results on Wednesday, May, 9th. The specialty pharmaceutical company reported ($0.91) earnings per share for the quarter, topping analysts' consensus estimates of ($0.94) by $0.03. The specialty pharmaceutical company earned $0.01 million during the quarter, compared to analyst estimates of $0.02 million. Paratek Pharmaceuticals had a negative net margin of 707.08% and a negative return on equity of 87.29%. View Paratek Pharmaceuticals' Earnings History.

What price target have analysts set for PRTK?

7 brokers have issued 12-month target prices for Paratek Pharmaceuticals' shares. Their forecasts range from $36.00 to $55.00. On average, they anticipate Paratek Pharmaceuticals' stock price to reach $45.00 in the next twelve months. View Analyst Ratings for Paratek Pharmaceuticals.

Are investors shorting Paratek Pharmaceuticals?

Paratek Pharmaceuticals saw a increase in short interest during the month of April. As of April 30th, there was short interest totalling 4,049,664 shares, an increase of 61.9% from the April 13th total of 2,500,701 shares. Based on an average trading volume of 1,122,559 shares, the days-to-cover ratio is presently 3.6 days. Currently, 15.7% of the shares of the company are sold short.

Who are some of Paratek Pharmaceuticals' key competitors?

Who are Paratek Pharmaceuticals' key executives?

Paratek Pharmaceuticals' management team includes the folowing people:
  • Mr. Michael F. Bigham, Chairman & CEO (Age 60)
  • Dr. Evan Loh, Pres, Chief Medical Officer, COO & Director (Age 59)
  • Mr. Douglas W. Pagán, Chief Financial Officer (Age 46)
  • Mr. William M. Haskel, Sr. VP, Gen. Counsel & Corp. Sec. (Age 56)
  • Mr. Adam Woodrow, Chief Commercial Officer and VP (Age 51)

Has Paratek Pharmaceuticals been receiving favorable news coverage?

News coverage about PRTK stock has been trending somewhat positive recently, according to Accern. The research firm scores the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Paratek Pharmaceuticals earned a daily sentiment score of 0.14 on Accern's scale. They also assigned media coverage about the specialty pharmaceutical company an impact score of 46.26 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

Who are Paratek Pharmaceuticals' major shareholders?

Paratek Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.42%), Highland Capital Management LP (3.04%), C WorldWide Group Holding A S (1.58%), Northern Trust Corp (1.14%), Water Island Capital LLC (0.81%) and JPMorgan Chase & Co. (0.72%). Company insiders that own Paratek Pharmaceuticals stock include Adam Woodrow, Douglas W Pagan, Evan Loh, Fund Iv LP Omega, Michael Bigham and Robert S Radie. View Institutional Ownership Trends for Paratek Pharmaceuticals.

Which institutional investors are selling Paratek Pharmaceuticals stock?

PRTK stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, C WorldWide Group Holding A S, Prosight Management LP, JPMorgan Chase & Co. and Opus Point Partners Management LLC. Company insiders that have sold Paratek Pharmaceuticals company stock in the last year include Adam Woodrow, Douglas W Pagan, Evan Loh, Michael Bigham and Robert S Radie. View Insider Buying and Selling for Paratek Pharmaceuticals.

Which institutional investors are buying Paratek Pharmaceuticals stock?

PRTK stock was bought by a variety of institutional investors in the last quarter, including Highland Capital Management LP, Omni Partners LLP, BlackRock Inc., California Public Employees Retirement System, Water Island Capital LLC, A.R.T. Advisors LLC, Trellus Management Company LLC and Northern Trust Corp. Company insiders that have bought Paratek Pharmaceuticals stock in the last two years include Fund Iv LP Omega and Michael Bigham. View Insider Buying and Selling for Paratek Pharmaceuticals.

How do I buy shares of Paratek Pharmaceuticals?

Shares of PRTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Paratek Pharmaceuticals' stock price today?

One share of PRTK stock can currently be purchased for approximately $10.30.

How big of a company is Paratek Pharmaceuticals?

Paratek Pharmaceuticals has a market capitalization of $328.60 million and generates $12.62 million in revenue each year. The specialty pharmaceutical company earns $-89,060,000.00 in net income (profit) each year or ($3.30) on an earnings per share basis. Paratek Pharmaceuticals employs 83 workers across the globe.

How can I contact Paratek Pharmaceuticals?

Paratek Pharmaceuticals' mailing address is 75 PARK PLAZA, BOSTON MA, 02116. The specialty pharmaceutical company can be reached via phone at 617-807-6600 or via email at [email protected]


MarketBeat Community Rating for Paratek Pharmaceuticals (PRTK)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  272 (Vote Outperform)
Underperform Votes:  203 (Vote Underperform)
Total Votes:  475
MarketBeat's community ratings are surveys of what our community members think about Paratek Pharmaceuticals and other stocks. Vote "Outperform" if you believe PRTK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRTK will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Paratek Pharmaceuticals (NASDAQ:PRTK) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
7 Wall Street analysts have issued ratings and price targets for Paratek Pharmaceuticals in the last 12 months. Their average twelve-month price target is $45.00, suggesting that the stock has a possible upside of 336.89%. The high price target for PRTK is $55.00 and the low price target for PRTK is $36.00. There are currently 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.143.14
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $45.00$45.00$42.7143$42.7143
Price Target Upside: 336.89% upside242.21% upside128.42% upside91.12% upside

Paratek Pharmaceuticals (NASDAQ:PRTK) Consensus Price Target History

Price Target History for Paratek Pharmaceuticals (NASDAQ:PRTK)

Paratek Pharmaceuticals (NASDAQ:PRTK) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/9/2018Cantor FitzgeraldSet Price TargetBuy$50.00LowView Rating Details
3/4/2018Leerink SwannReiterated RatingOutperformLowView Rating Details
3/2/2018HC WainwrightBoost Price TargetBuy ➝ Buy$43.00 ➝ $55.00HighView Rating Details
3/2/2018Raymond JamesReiterated RatingStrong-Buy ➝ Outperform$36.00HighView Rating Details
3/2/2018UBSDowngradeStrong-Buy ➝ OutperformHighView Rating Details
10/24/2017Robert W. BairdReiterated RatingBuy$40.00N/AView Rating Details
10/24/2017GuggenheimInitiated CoverageBuy$44.00N/AView Rating Details
4/4/2017BTIG ResearchBoost Price TargetBuy$47.00 ➝ $56.00MediumView Rating Details
4/3/2017WedbushReiterated RatingOutperform ➝ Outperform$30.00HighView Rating Details
6/17/2016Ladenburg ThalmannBoost Price TargetBuy$46.00 ➝ $52.00N/AView Rating Details
(Data available from 5/26/2016 forward)

Earnings

Paratek Pharmaceuticals (NASDAQ:PRTK) Earnings History and Estimates Chart

Earnings by Quarter for Paratek Pharmaceuticals (NASDAQ:PRTK)

Paratek Pharmaceuticals (NASDAQ:PRTK) Earnings Estimates

2018 EPS Consensus Estimate: ($3.63)
2019 EPS Consensus Estimate: ($4.89)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.91)($0.86)($0.89)
Q2 20182($0.94)($0.90)($0.92)
Q3 20182($0.98)($0.48)($0.73)
Q4 20182($1.16)($1.02)($1.09)
Q1 20192($3.54)($0.85)($2.20)
Q2 20191($0.88)($0.88)($0.88)
Q3 20191($0.89)($0.89)($0.89)
Q4 20191($0.92)($0.92)($0.92)

Paratek Pharmaceuticals (NASDAQ PRTK) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2018Q1($0.94)($0.91)$0.02 million$0.01 millionViewListenView Earnings Details
3/1/2018Q4 2017($0.75)($0.7840)$5.00 million$5.07 millionViewN/AView Earnings Details
11/8/2017Q3 2017($0.93)($0.77)$0.01 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.89)($0.64)$7.50 million$7.51 millionViewListenView Earnings Details
5/4/2017Q1 2017($1.2010)($1.14)$0.02 millionViewListenView Earnings Details
3/2/2017Q4 2016($1.3290)($1.1650)$0.03 millionViewListenView Earnings Details
11/2/2016($1.38)($1.04)ViewN/AView Earnings Details
8/4/2016Q2 2016($1.66)($1.69)ViewN/AView Earnings Details
5/2/2016($1.25)($1.77)ViewN/AView Earnings Details
2/23/2016Q4($1.18)($1.20)ViewListenView Earnings Details
11/12/2015Q315($0.91)($1.33)ViewListenView Earnings Details
8/5/2015Q215($0.75)($0.94)$3.62 billionViewN/AView Earnings Details
5/15/2015Q1 2015($2.16)($0.96)ViewN/AView Earnings Details
4/2/2015Q1($2.16)($0.74)$0.13 million$4.00 millionViewN/AView Earnings Details
5/5/2014($0.18)($0.15)$0.42 millionViewN/AView Earnings Details
3/13/2014Q413($0.21)($0.29)$0.50 million$0.3160 millionViewN/AView Earnings Details
11/7/2013Q3 2013($2.52)($3.00)$0.10 million$0.38 millionViewN/AView Earnings Details
8/7/2013Q2 2013($3.48)($2.40)$0.20 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.42)($0.56)($5.83) millionViewN/AView Earnings Details
2/27/2013Q4 2012($3.12)($4.20)ViewN/AView Earnings Details
11/12/2012Q312$0.06$0.25$8.37 million$10.44 millionViewN/AView Earnings Details
8/13/2012Q2 2012($3.60)($3.60)ViewN/AView Earnings Details
5/14/2012Q1 2012($5.28)($4.47)ViewN/AView Earnings Details
3/14/2012Q4 2011$4.20$4.42ViewN/AView Earnings Details
11/10/2011Q3 2011($4.92)($4.43)ViewN/AView Earnings Details
8/11/2011Q2 2011($3.36)($2.04)ViewN/AView Earnings Details
5/16/2011Q1 2011($3.24)($1.68)ViewN/AView Earnings Details
3/16/2011Q4 2010($3.36)($2.35)ViewN/AView Earnings Details
11/11/2010Q3 2010($2.64)($2.47)ViewN/AView Earnings Details
8/9/2010Q2 2010($1.80)($1.85)ViewN/AView Earnings Details
5/12/2010Q1 2010($2.04)($1.66)ViewN/AView Earnings Details
3/23/2010Q4 2009($2.76)($2.11)ViewN/AView Earnings Details
11/12/2009Q3 2009($0.12)($3.47)ViewN/AView Earnings Details
8/14/2009Q2 2009($6.53)ViewN/AView Earnings Details
5/13/2009Q1 2009($11.38)ViewN/AView Earnings Details
3/23/2009Q4 2008($15.71)ViewN/AView Earnings Details
11/10/2008Q3 2008($15.97)ViewN/AView Earnings Details
5/12/2008Q1 2008($13.21)($2.76)ViewN/AView Earnings Details
3/17/2008Q4 2007($5.40)($6.24)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Paratek Pharmaceuticals (NASDAQ:PRTK) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/14/2014special$1.336/4/20145/26/20146/3/2014
(Data available from 1/1/2013 forward)

Insider Trades

Paratek Pharmaceuticals (NASDAQ PRTK) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.20%
Institutional Ownership Percentage: 77.40%
Insider Trading History for Paratek Pharmaceuticals (NASDAQ:PRTK)
Insider Trading History for Paratek Pharmaceuticals (NASDAQ:PRTK)

Paratek Pharmaceuticals (NASDAQ PRTK) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/9/2018Adam WoodrowVPSell5,700$12.70$72,390.0089,167View SEC Filing  
4/9/2018Douglas W PaganCFOSell5,237$12.70$66,509.9077,083View SEC Filing  
4/9/2018Evan LohCOOSell8,084$12.70$102,666.80214,786View SEC Filing  
4/9/2018Michael BighamChairmanSell8,700$12.70$110,490.00199,730View SEC Filing  
2/6/2018Adam WoodrowVPSell14,333$13.87$198,798.7162,367View SEC Filing  
2/5/2018Douglas W PaganCFOSell16,291$14.22$231,658.0239,570View SEC Filing  
2/5/2018Evan LohCOOSell3,040$14.22$43,228.80144,870View SEC Filing  
2/5/2018Michael BighamChairmanSell4,000$14.22$56,880.00123,680View SEC Filing  
2/5/2018Robert S RadieDirectorSell3,000$14.22$42,660.009,330View SEC Filing  
7/5/2017Adam WoodrowVPSell3,800$23.58$89,604.0069,500View SEC Filing  
7/5/2017Douglas W PaganCFOSell4,139$23.58$97,597.6260,000View SEC Filing  
7/5/2017Evan LohCOOSell4,351$23.58$102,596.58112,783View SEC Filing  
7/5/2017Michael BighamChairmanSell5,075$23.58$119,668.50109,500View SEC Filing  
6/19/2017Douglas W PaganCFOSell4,595$25.00$114,875.0051,000View SEC Filing  
2/6/2017Douglas W PaganCFOSell3,405$15.09$51,381.4558,983View SEC Filing  
2/6/2017Evan LohCOOSell3,106$15.09$46,869.54102,873View SEC Filing  
2/6/2017Michael BighamChairmanSell5,000$15.09$75,450.0099,970View SEC Filing  
6/27/2016Fund Iv L.P. OmegaMajor ShareholderBuy461,538$13.00$5,999,994.00View SEC Filing  
6/23/2016Michael BighamCEOBuy20,000$13.45$269,000.00100,000View SEC Filing  
12/11/2015Evan LohCMOBuy2,300$16.87$38,801.0080,389View SEC Filing  
5/29/2015Hbm Healthcare Investments (CaMajor ShareholderSell20,580$30.75$632,835.00View SEC Filing  
12/13/2013Roumell Asset Management, Llcmajor shareholderSell1,470$3.54$5,203.80View SEC Filing  
12/11/2013Roumell Asset Management, Llcmajor shareholderSell10,490$3.55$37,239.50View SEC Filing  
12/6/2013Roumell Asset Management, Llcmajor shareholderSell8,710$3.54$30,833.40View SEC Filing  
12/4/2013Roumell Asset Management, Llcmajor shareholderSell7,120$3.50$24,920.00View SEC Filing  
11/20/2013Roumell Asset Management, Llcmajor shareholderSell10,040$3.57$35,842.80View SEC Filing  
11/12/2013Roumell Asset Management, Llcmajor shareholderSell7,190$3.53$25,380.70View SEC Filing  
11/7/2013Roumell Asset Management, Llcmajor shareholderSell4,960$3.61$17,905.60View SEC Filing  
10/30/2013Roumell Asset Management, LlcMajor ShareholderSell7,020$3.69$25,903.80View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Paratek Pharmaceuticals (NASDAQ PRTK) News Headlines

Source:
DateHeadline
Paratek Pharmaceuticals (PRTK) Reports New Analysis Highlighting Efficacy of Omadacycline in Treating Community ...Paratek Pharmaceuticals (PRTK) Reports New Analysis Highlighting Efficacy of Omadacycline in Treating Community ...
www.streetinsider.com - May 24 at 4:45 PM
Cantor Fitzgerald Research Analysts Cut Earnings Estimates for Paratek Pharmaceuticals, Inc. (PRTK)Cantor Fitzgerald Research Analysts Cut Earnings Estimates for Paratek Pharmaceuticals, Inc. (PRTK)
www.americanbankingnews.com - May 24 at 8:22 AM
Paratek Presents New Analysis Highlighting Efficacy of Omadacycline in Treating Community-Acquired Bacterial Pneumonia by Measures of Disease SeverityParatek Presents New Analysis Highlighting Efficacy of Omadacycline in Treating Community-Acquired Bacterial Pneumonia by Measures of Disease Severity
finance.yahoo.com - May 22 at 4:34 PM
What Investors Should Know About Paratek Pharmaceuticals Inc’s (NASDAQ:PRTK) Financial StrengthWhat Investors Should Know About Paratek Pharmaceuticals Inc’s (NASDAQ:PRTK) Financial Strength
finance.yahoo.com - May 21 at 4:36 PM
Equities Analysts Issue Forecasts for Paratek Pharmaceuticals, Inc.s Q2 2018 Earnings (PRTK)Equities Analysts Issue Forecasts for Paratek Pharmaceuticals, Inc.'s Q2 2018 Earnings (PRTK)
www.americanbankingnews.com - May 21 at 1:04 AM
Gabelli Research Analysts Decrease Earnings Estimates for Paratek Pharmaceuticals, Inc. (PRTK)Gabelli Research Analysts Decrease Earnings Estimates for Paratek Pharmaceuticals, Inc. (PRTK)
www.americanbankingnews.com - May 14 at 5:11 AM
Paratek Pharmaceuticals, Inc. (PRTK) to Post Q2 2018 Earnings of ($0.94) Per Share, Leerink Swann ForecastsParatek Pharmaceuticals, Inc. (PRTK) to Post Q2 2018 Earnings of ($0.94) Per Share, Leerink Swann Forecasts
www.americanbankingnews.com - May 14 at 1:56 AM
Paratek Pharmaceuticals, Inc. (PRTK) Receives Average Rating of "Buy" from BrokeragesParatek Pharmaceuticals, Inc. (PRTK) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 13 at 3:33 AM
Paratek Pharmaceuticals, Inc. (PRTK) Sees Significant Growth in Short InterestParatek Pharmaceuticals, Inc. (PRTK) Sees Significant Growth in Short Interest
www.americanbankingnews.com - May 12 at 1:06 AM
Paratek Pharmaceuticals (PRTK) Releases Quarterly  Earnings Results, Beats Expectations By $0.03 EPSParatek Pharmaceuticals (PRTK) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS
www.americanbankingnews.com - May 10 at 4:46 PM
Edited Transcript of PRTK earnings conference call or presentation 9-May-18 12:30pm GMTEdited Transcript of PRTK earnings conference call or presentation 9-May-18 12:30pm GMT
finance.yahoo.com - May 10 at 9:27 AM
Paratek Pharmaceuticals (PRTK) PT Set at $50.00 by Cantor FitzgeraldParatek Pharmaceuticals (PRTK) PT Set at $50.00 by Cantor Fitzgerald
www.americanbankingnews.com - May 9 at 6:23 PM
Paratek Pharmaceuticals (PRTK) CEO Michael Bigham on Q1 2018 Results - Earnings Call TranscriptParatek Pharmaceuticals' (PRTK) CEO Michael Bigham on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 9 at 4:43 PM
Paratek up 1% on Q1 resultParatek up 1% on Q1 result
seekingalpha.com - May 9 at 9:17 AM
5 Biotech Stocks Set to Beat Estimates This Earnings Season5 Biotech Stocks Set to Beat Estimates This Earnings Season
finance.yahoo.com - May 9 at 9:17 AM
Paratek: 1Q Earnings SnapshotParatek: 1Q Earnings Snapshot
finance.yahoo.com - May 9 at 9:17 AM
Paratek Pharmaceuticals Reports First Quarter 2018 Financial ResultsParatek Pharmaceuticals Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 9 at 9:17 AM
Is Paratek Pharmaceuticals Oversold?Is Paratek Pharmaceuticals Oversold?
seekingalpha.com - May 3 at 9:06 AM
Paratek Pharmaceuticals, Inc. (PRTK) Short Interest UpdateParatek Pharmaceuticals, Inc. (PRTK) Short Interest Update
www.americanbankingnews.com - April 29 at 3:12 AM
Paratek Pharmaceuticals to Report First Quarter 2018 Financial Results on May 9, 2018Paratek Pharmaceuticals to Report First Quarter 2018 Financial Results on May 9, 2018
finance.yahoo.com - April 26 at 9:03 AM
Paratek Pharmaceuticals Presents Data Supporting Potential Approval of Omadacycline for Treatment of Community ...Paratek Pharmaceuticals Presents Data Supporting Potential Approval of Omadacycline for Treatment of Community ...
globenewswire.com - April 25 at 4:47 PM
Paratek Pharmaceuticals (PRTK) to Release Earnings on WednesdayParatek Pharmaceuticals (PRTK) to Release Earnings on Wednesday
www.americanbankingnews.com - April 25 at 6:32 AM
Paratek Pharmaceuticals (PRTK) Downgraded by BidaskClub to Strong SellParatek Pharmaceuticals (PRTK) Downgraded by BidaskClub to Strong Sell
www.americanbankingnews.com - April 24 at 9:58 AM
Parateks omadacycline on par with moxifloxacin in late-stage study in CABPParatek's omadacycline on par with moxifloxacin in late-stage study in CABP
seekingalpha.com - April 23 at 4:36 PM
Paratek Pharmaceuticals (PRTK) Prices $140 Million of Convertible Senior Subordinated Notes due 2024Paratek Pharmaceuticals (PRTK) Prices $140 Million of Convertible Senior Subordinated Notes due 2024
www.streetinsider.com - April 20 at 9:23 AM
Heres Why Paratek Pharmaceuticals Dropped as Much as 16.6% TodayHere's Why Paratek Pharmaceuticals Dropped as Much as 16.6% Today
www.msn.com - April 19 at 4:49 PM
Here's Why Paratek Pharmaceuticals Dropped as Much as 16.6% TodayHere's Why Paratek Pharmaceuticals Dropped as Much as 16.6% Today
finance.yahoo.com - April 19 at 4:49 PM
Paratek Pharmaceuticals (PRTK) Announces Proposed Private Offering of $125 Million of Convertible Senior Subordinated Notes due 2024Paratek Pharmaceuticals (PRTK) Announces Proposed Private Offering of $125 Million of Convertible Senior Subordinated Notes due 2024
www.streetinsider.com - April 19 at 9:11 AM
Paratek Pharmaceuticals, Inc. Prices $140 Million of Convertible Senior Subordinated Notes due 2024Paratek Pharmaceuticals, Inc. Prices $140 Million of Convertible Senior Subordinated Notes due 2024
finance.yahoo.com - April 19 at 9:11 AM
Paratek Pharma launches $125M convertible debt offeringParatek Pharma launches $125M convertible debt offering
seekingalpha.com - April 18 at 4:54 PM
Paratek Pharmaceuticals, Inc. Announces Proposed Private Offering of $125 Million of Convertible Senior Subordinated Notes due 2024Paratek Pharmaceuticals, Inc. Announces Proposed Private Offering of $125 Million of Convertible Senior Subordinated Notes due 2024
finance.yahoo.com - April 18 at 4:54 PM
Brokers Set Expectations for Paratek Pharmaceuticals, Inc.s Q1 2018 Earnings (PRTK)Brokers Set Expectations for Paratek Pharmaceuticals, Inc.'s Q1 2018 Earnings (PRTK)
www.americanbankingnews.com - April 18 at 7:52 AM
Paratek Pharmaceuticals, Inc. (PRTK) Receives Average Recommendation of "Buy" from AnalystsParatek Pharmaceuticals, Inc. (PRTK) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 18 at 3:21 AM
Paratek Pharmaceuticals (PRTK) Price Target Raised to $43.00Paratek Pharmaceuticals (PRTK) Price Target Raised to $43.00
www.americanbankingnews.com - April 17 at 7:34 PM
Analysts Offer Predictions for Paratek Pharmaceuticals, Inc.s FY2020 Earnings (PRTK)Analysts Offer Predictions for Paratek Pharmaceuticals, Inc.'s FY2020 Earnings (PRTK)
www.americanbankingnews.com - April 17 at 7:05 AM
BidaskClub Downgrades Paratek Pharmaceuticals (PRTK) to BuyBidaskClub Downgrades Paratek Pharmaceuticals (PRTK) to Buy
www.americanbankingnews.com - April 16 at 5:24 PM
Technical Perspectives on Biotech Stocks -- Pain Therapeutics, Paratek Pharma, PDL BioPharma, and Progenics ...Technical Perspectives on Biotech Stocks -- Pain Therapeutics, Paratek Pharma, PDL BioPharma, and Progenics ...
www.prnewswire.com - April 16 at 9:07 AM
BRIEF-Paratek Appoints Rolf Hoffman To Cos Board Of DirectorsBRIEF-Paratek Appoints Rolf Hoffman To Co's Board Of Directors
www.reuters.com - April 14 at 4:25 PM
Paratek Pharmaceuticals (PRTK) Names Rolf K. Hoffman to BoardParatek Pharmaceuticals (PRTK) Names Rolf K. Hoffman to Board
www.streetinsider.com - April 14 at 4:25 PM
Paratek Pharmaceuticals (PRTK) Rating Increased to Sell at BidaskClubParatek Pharmaceuticals (PRTK) Rating Increased to Sell at BidaskClub
www.americanbankingnews.com - April 14 at 10:43 AM
Paratek Appoints Rolf K. Hoffman to Company’s Board of DirectorsParatek Appoints Rolf K. Hoffman to Company’s Board of Directors
finance.yahoo.com - April 14 at 9:22 AM
Paratek Pharmaceuticals Presenting New Data from Omadacycline Development Program at ECCMID 2018Paratek Pharmaceuticals Presenting New Data from Omadacycline Development Program at ECCMID 2018
finance.yahoo.com - April 12 at 10:03 AM
Evan Loh Sells 8,084 Shares of Paratek Pharmaceuticals Inc (PRTK) StockEvan Loh Sells 8,084 Shares of Paratek Pharmaceuticals Inc (PRTK) Stock
www.americanbankingnews.com - April 10 at 10:16 PM
Paratek Pharmaceuticals Inc (PRTK) Chairman Michael Bigham Sells 8,700 SharesParatek Pharmaceuticals Inc (PRTK) Chairman Michael Bigham Sells 8,700 Shares
www.americanbankingnews.com - April 10 at 10:16 PM
Insider Selling: Paratek Pharmaceuticals Inc (PRTK) VP Sells 5,700 Shares of StockInsider Selling: Paratek Pharmaceuticals Inc (PRTK) VP Sells 5,700 Shares of Stock
www.americanbankingnews.com - April 10 at 10:16 PM
Douglas W. Pagan Sells 5,237 Shares of Paratek Pharmaceuticals Inc (PRTK) StockDouglas W. Pagan Sells 5,237 Shares of Paratek Pharmaceuticals Inc (PRTK) Stock
www.americanbankingnews.com - April 10 at 10:16 PM
Paratek Pharmaceuticals (PRTK) Upgraded to Buy by BidaskClubParatek Pharmaceuticals (PRTK) Upgraded to Buy by BidaskClub
www.americanbankingnews.com - April 10 at 8:55 PM
Paratek Pharmaceuticals (PRTK) Presents At H. C. Wainwright Global Life Sciences Conference - SlideshowParatek Pharmaceuticals (PRTK) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow
seekingalpha.com - April 10 at 4:40 PM
Paratek Pharmaceuticals (PRTK) Now Covered by Analysts at GuggenheimParatek Pharmaceuticals (PRTK) Now Covered by Analysts at Guggenheim
www.americanbankingnews.com - April 5 at 8:30 PM
Parateks (PRTK) NDA for Oral and Intravenous Omadacycline Accepted for Priority Review by FDAParatek's (PRTK) NDA for Oral and Intravenous Omadacycline Accepted for Priority Review by FDA
www.streetinsider.com - April 5 at 4:37 PM

SEC Filings

Paratek Pharmaceuticals (NASDAQ:PRTK) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Paratek Pharmaceuticals (NASDAQ:PRTK) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Paratek Pharmaceuticals (NASDAQ PRTK) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.